The U.S. Senate Judiciary Committee recently voted on a set of six drug patent-related bills aimed at reducing consumer drug prices. While the committee chair, Senator Chuck Grassley, emphasized the need to tackle high drug prices caused by anti-competitive behaviors, questions arose about whether these measures would hinder pharmaceutical innovation. Senator Lee raised a critical point regarding the fairness of legal processes for companies amidst these legislative changes. The ongoing discussions indicate a balancing act between consumer affordability and promoting industry advancement.
"While Senator Lee agreed that minimizing sham petitions would be beneficial, he argued that legislating such a presumption would turn a company's day in court into 'a blunted opportunity for due process.'"},{
Collection
[
|
...
]